Year: 2011
Type: article
Abstract: The American Society of Gene and Cell Therapy (ASGCT) is in a period of strategic planning. Although this is by no means an indication of a midlife crisis, it clearly coincides with a time for necessary reassessment. The Society has broadened its remit to fully incorporate cellular therapies (a change in job), the success of gene therapies in a range of diseases has meant that investigators in those fields may now strengthen their association with disease-specific societies and weaken their links with ASGCT (kids leaving home), and science funding in general will undoubtedly become harder to obtain (vigor and health not what they were).
Source: Molecular Therapy
DOI: 10.1038/mt.2011.66
Author: Malcolm K Brenner
Language: English
Subfield: Genetics
Domain: Life Sciences
Open Access status: hybrid
Estimated APC paid: $4,500
OpenAlex ID: W4245528765